Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Dompe Farmaceutici SpA | 14 |
| 2 | GlaxoSmithKline Intellectual Property No 2 Ltd | 14 |
| 3 | Pulmatrix Operating Co Inc | 14 |
| 4 | Dompe SpA | 8 |
| 5 | University of Utah Research Foundation Inc | 8 |
| 6 | Centre National de la Recherche Scientifique | 7 |
| 7 | Duke University | 7 |
| 8 | Pulmatrix Inc | 7 |
| 9 | BASF SE | 5 |
| 10 | Boston Children's Hospital | 5 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 225 |
| 2 | A61K | Medicinal preparations | 194 |
| 3 | C07D | Heterocyclic compounds | 112 |
| 4 | C07K | Peptides | 46 |
| 5 | C12N | Microorganisms, enzymes | 40 |
| 6 | G01N | Investigating / analysing materials | 29 |
| 7 | C07F | Organometallic compounds | 26 |
| 8 | A01K | 14 | |
| 9 | C12Q | Measuring/testing involving enzymes | 13 |
| 10 | A61B | 12 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Novel application of TRPV4 agonist GSK1016790A | 2020 | University of South China | 3 |
| Application of GSK1016790A in preparation of medicine for treating or relieving diabetic enteropathy | 2024 | THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA | 0 |
| Application of GSK1016790A in preparing medicine for treating or relieving diabetic enteropathy | 2022 | THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Ion Channels and Receptors | 2 |
| 2 | Gastrointestinal motility and disorders | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | David Križaj | University of Utah | 7 |
| 2 | Lei Chen | Nanjing Medical University | 7 |
| 3 | Ajit Jadhav | National Center for Advancing Translational Sciences | 4 |
| 4 | Anton Simeonov | National Center for Advancing Translational Sciences | 4 |
| 5 | Chunfeng Wu | Second Affiliated Hospital of Nanjing Medical University | 4 |
| 6 | Dong An | Nanjing Medical University | 4 |
| 7 | Carleen Klumpp‐Thomas | National Center for Advancing Translational Sciences | 3 |
| 8 | Chen Men | Nanjing Medical University | 3 |
| 9 | Hongmao Sun | National Center for Advancing Translational Sciences | 3 |
| 10 | Li Zhou | Nanjing Medical University | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Elementary Ca <sup>2+</sup> Signals Through Endothelial TRPV4 Channels Regulate Vascular Function | 2012 | 548 | Nitric Oxide and Endothelin Effects |
| Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis | 2010 | 410 | Urinary Bladder and Prostate Research |
| N-((1 S)-1-{[4-((2 S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a Novel and Potent Transient Receptor Potential Vanilloid 4 Channel Agonist Induces Urinary Bladder Contraction and Hyperactivity: Part I | 2008 | 407 | Urinary Bladder and Prostate Research |
| TRPV4-mediated endothelial Ca<sup>2+</sup> influx and vasodilation in response to shear stress | 2009 | 336 | Ion Channels and Receptors |
| Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2 | 2008 | 299 | Heart Rate Variability and Autonomic Control |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of GSK1016790A?
Which organizations hold the most patents for GSK1016790A?
What is the primary mechanism of action studied in the highest-cited paper?
How many papers and patents have been published on GSK1016790A in the last three years?
What medical applications have been disclosed in recent patent filings?